Skip to main content

Table 7 Pregnancy outcome by exposure group, according to anti-malarial drug exposure during the first trimester

From: Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia

 

Exposure to anti-malarial(s) during first trimester

 

AL only

(N = 150)

AL plus SP

(N = 9)

SP or/and quinine

(N = 135)

None

(N = 684)

Unknown

(N = 42)

Pregnancy outcome - n (%)

Abortion (≤28 weeks)

4 (2.7)

2 (22.2)

0 (-)

8* (1.2)

1** (2.4)

Stillbirth (>28 weeks)

2 (1.3)

0 (-)

3 (2.2)

17 (2.5)

0 (-)

Preterm delivery (<37 weeks)

20 (13.3)

1 (11.1)

28 (20.7)

104 (15.2)

8 (19.0)

Full term delivery (≥37 weeks)

113 (75.3)

6 (66.7)

98 (72.6)

523 (76.5)

32 (76.2)

Unknown (mother withdrawn prior to delivery)

11 (7.3)

0 (-)

6 (4.4)

32 (4.7)

1 (2.4)

  1. Enrolled population: newborns, stillbirths and aborted foetuses
  2. AL = artemether-lumefantrine; SP = sulphadoxine-pyrimethamine
  3. *5 abortions: one woman with triplets, one with twins
  4. ** Incomplete date of last menstrual period, therefore, counted as unknown first trimester exposure (a woman who was likely to have taken AL during the first trimester)
Back to article page

Malaria Journal

ISSN: 1475-2875

Contact us